Skip to main content

IBA Business Update – First Quarter 2021

Louvain-La-Neuve, Belgium, 20 May 2021 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its business update for the first quarter ending 31 March 2021. Group Overview ▪ Strong balance sheet maintained, with EUR 152 million unaudited gross cash (31 Dec 2020: EUR 151.3 million) and EUR 72.6 million unaudited net cash (31 Dec 2020: EUR 65.2 million) ▪ Business operations have remained solid into the first quarter of 2021, albeit with some continuing impact from COVID-19 related installation delays in Proton Therapy alongside some Other Accelerator delays ▪ Continued focus on sustainable growth and profitability, delivering the very best offering and services to our customers, whilst remaining committed to corporate responsibility ▪ As part of a long-term employee incentive plan, IBA’s share buyback program was launched in January 2021 and is almost complete Olivier Legrain, Chief Executive Officer of IBA commented: “I have been pleased to see IBA’s continued resilience in the first quarter of 2021, with growing momentum in Proton Therapy in the US, continued success in Asia and strong performance in our Dosimetry and Other Accelerators businesses.” “Our roadmap to sustainable growth and profitability is clear: capitalize on our market leading position globally, invest for strategic impact and deliver operational execution. This focus will be reinforced by our continuing commitment to our customers, our employees and to the planet and I am proud of the groundwork we are laying as a company towards a true stakeholder approach to our business.”
See more


IntegraLab PLUS


Care Program


Cyclone 30


RadioPharma Solutions



rigging cyclone kiube coimbra

The Impressive Rigging of the Cyclone KIUBE Through a Shielded Door

Thanks to its compact design, the Cyclone® KIUBE entered through the door of the existing vault! This technical exploit can be achieved only by IBA.

video Loader

Maximize your production capacity with the Synthera+


The IFP™ Loader* enables you to carry out independent multiple runs of multiple molecules or of a single tracer.Four consecutive runs can be performed without opening the hot cell with ZERO radiation exposure to the operator and ZERO downtime between runs.You can add up to 3 Synthera®+ with the IFP Loader within the same selected hot cell: up to 12 runs of multiple tracers without opening the hot cell!More capacity with the benefit of not having to invest in more hot cells.

* Patent application EP3308852A1

Integralab - Users Voice Coimbra

Successful collaboration to establish a (c)GMP-compliant radiopharmacy

Antero Abrunhosa, head of the radiochemistry laboratory of the Institute of Nuclear Sciences Applied to health (ICNAS) in Coimbra, Portugal presents the successful collaboration with IBA to establish the ICNAS GMP PET center.


IBA integralab presentation

INTEGRALAB®PLUS is a fully integrated solution, combining equipment and services for establishing a radiopharmaceutical GMP production centre tailored to your precise needs. Our approach is truly comprehensive, taking your project from building design through to ongoing production with full regulatory compliance and the selection, integration, installation and qualification of equipment that meets your radioisotope production goals